Natural History Study of Patients With Hypophosphatasia (HPP)
Natural History Study of Adult and Pediatric Patients With Hypophosphatasia
Duke University
200 participants
Sep 1, 2014
OBSERVATIONAL
Conditions
Summary
Hypophosphatasia (HPP) is a rare inherited metabolic disorder characterized by defective bone and teeth mineralization caused by mutations of the ALPL gene, which encodes for the tissue-nonspecific alkaline phosphatase (TNSALP) isozyme, resulting in decreased serum and bone alkaline phosphatase levels. To date, over 250 different mutations in the gene encoding TNSALP have been associated with HPP. Clinically, the loss of TNSALP function results in progressive skeletal impact as well as progressive impact on all other major organ systems. It clinically manifests as rickets in infants and children and osteomalacia at all ages. The severe form of the disease has been estimated to have a prevalence of about 1 in every 100,000 live births.
Eligibility
Inclusion Criteria7
- Patients or their legal representative must provide written informed consent or, if applicable, qualify for waiver of consent.
- Patients must have a pre-established clinical diagnosis of HPP, as indicated by one or more of the following:
- Serum alkaline phosphatase (ALP) below the age-adjusted normal range
- Plasma PLP at least twice the upper limit of normal (no vitamin B6 administered for at least 1 week prior to determination)
- Evidence of osteopenia or osteomalacia on skeletal radiographs
- Genetic analysis fof the ALPL gene
- Must be current patient in the Duke University System.
Exclusion Criteria1
- Any patient without confirmation of clinical diagnosis of HPP.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02237625